Evaluation of 68-Ga PSMA PET/CT imaging in individuals with biochemical recurrence following radical prostatectomy

Chris Rothe1,2, Yuigi Yuminaga1, Jonathan Kam1, Sunny Nalavenkata1, Mohan Arianayagam1, Bertram Canagasingham1, Richard Ferguson1, Raymond Ko1, Celi Varol1, Han Loh2, Deepa Shetty2, Chuong Bui2, Diep Nguyen2, Ken Le2, Mohamed Khadra1, Matthew Winter1.

1 Nepean Urology Research Group (NURG), Kingswood, NSW, Australia
2 Nepean Radiology Research Group, Kingswood, NSW, Australia

INTRODUCTION
Prostate specific membrane antigen (PSMA) is a transmembrane protein that is expressed in most prostate cancers, thus presenting a unique imaging target for the detection of prostate cancer recurrence. This study aimed to investigate the correlation between prostate specific antigen (PSA) level and positive findings on the 68Ga-PSMA PET/CT (PSMA PET) scan in patients with biochemical recurrence following radical prostatectomy.

METHOD
We conducted a retrospective analysis of our institutional prospective database between February 2015 to August 2017 to identify patients with biochemical recurrence (BCR) who underwent PSMA PET scans following radical prostatectomy for prostate cancer.

The probability of a positive PSMA scan with BCR was then analysed. A maximum SUV of 2.6 in locations not associated with physiologic or reactive uptake on PSMA PET was deemed consistent with a positive scan.

Three hundred and ninety one patients met the inclusion criteria for the study. The median PSA level at the time of the initial PSMA PET was 2.05ng/ml with a range between 0.01-36ng/ml.

The detection rate of PSMA PET increased with higher levels of PSA. With PSA levels lower than 0.5ng/ml, detection rates were less than 50%. This improved to 92% successful detection of a focus of recurrent disease with PSA levels > 2.0ng/ml. Across the range of PSA values, soft tissue (nodal) disease is more frequently identified when compared to local recurrence or skeletal disease.

Table 1 (L) Detection rates of PSMA PET following radical prostatectomy based on PSA banding

<table>
<thead>
<tr>
<th>PSA level</th>
<th>Sample size</th>
<th>Number of positive patients</th>
<th>Detection rate (%)</th>
<th>PSA level</th>
<th>Bone (%)</th>
<th>Nodal (%)</th>
<th>Local (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.2ng/ml</td>
<td>97</td>
<td>41</td>
<td>42%</td>
<td>0.2-&lt;0.5ng/ml</td>
<td>13 (27%)</td>
<td>28 (54%)</td>
<td>15 (31%)</td>
</tr>
<tr>
<td>0.2-&lt;0.5ng/ml</td>
<td>101</td>
<td>48</td>
<td>48%</td>
<td>0.5-&lt;1.0ng/ml</td>
<td>7 (19%)</td>
<td>28 (76%)</td>
<td>7 (19%)</td>
</tr>
<tr>
<td>0.5-&lt;1.0ng/ml</td>
<td>54</td>
<td>36</td>
<td>67%</td>
<td>1.0-&lt;2.0ng/ml</td>
<td>13 (39%)</td>
<td>22 (67%)</td>
<td>9 (27%)</td>
</tr>
<tr>
<td>1.0-&lt;2.0ng/ml</td>
<td>39</td>
<td>33</td>
<td>85%</td>
<td>&gt;2.0ng/ml</td>
<td>20 (32%)</td>
<td>66 (72%)</td>
<td>36 (39%)</td>
</tr>
<tr>
<td>Total (overall)</td>
<td>391</td>
<td>250</td>
<td>64%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2 (R) Regions of detection of PSMA PET following radical prostatectomy based on PSA banding

CONCLUSIONS
There is a positive correlation with increasing PSA levels and the detection rates of recurrent prostate cancer utilising PSMA PET. With PSA levels greater than 1.0ng/ml, the clinical utility appears readily noted.

Further analysis of pathological features such as tumour grade, stage, margin status and lymphovascular involvement may provide additional information regarding correlation between PSMA PET results and recurrent disease.

Furthermore, the impact on treatment of PSMA PET results needs to be evaluated for it’s use in the management of patients with recurrent disease.